Draft, not yet released. In stewardship review. Not indexed until the first approved release.

The 2027 agenda

Eight bounded questions open the 2027 genomics agenda. Each comes from a baseline finding, names the initiative that will carry it and the first output due in the 2027 genomics edition.

5 min read0 figures6 tables5 notesNR-XTECH-GENOMICS-GLOBAL-2026-BASELINE

Contents
  1. ·Edition home
  2. ·Executive summary
  3. 1Genomics is data infrastructure and a therapeutic frontier
  4. 2Key findings
  5. 3Systems and sectors at baseline
  6. 4Risks and capability
  7. 5Individualised editing outpaces delivery systems
  8. 6Readings from the other desks
  9. 7The 2027 agenda
    1. 7.1 Questions for the operational series
    2. 7.2 Portfolio proposed for the Q1 2027 alignment
    3. 7.3 The pathway
    4. 7.4 Universe 2027: evidence pack for the genomics candidate mission
    5. 7.5 Handoffs and routing
    6. 7.6 Feeds and signal register
  10. 8Systems in depth
  11. AMethodology
  12. BData appendix
  13. CReferences and record
  14. ·Complete edition, for print

7.1Questions for the operational series

  1. Q-01

    How many patients are treated with editing therapies, at what price, and where are the access gaps?

    INI-XT05-DLV-01 · delivery and access; first output: treatment and price register.

  2. Q-02

    What energy, cooling and cold-chain load do sequencing and cell therapies carry?

    INI-XT05-ENE-02 · footprint of genomics; first output: footprint estimates by activity.

  3. Q-03

    What do sequencing and therapy costs look like on an independent basis?

    INI-XT05-CST-03 · cost on a common basis; first output: cost table.

  4. Q-04

    Which instruments, consumables and reagents are single points of failure?

    INI-XT05-SUP-04 · sequencer supply; first output: dependence map.

  5. Q-05

    How balanced are genome datasets by ancestry on a common basis?

    INI-XT05-DIV-05 · dataset balance; first output: ancestry table.

  6. Q-06

    Which national rules cover genetic data, somatic editing and heritable editing?

    To be admitted in 2027; first output: rule overlay.

  7. Q-07

    What workforce exists for genetic counselling, laboratory work and bioinformatics?

    To be admitted in 2027; first output: scoping note.

  8. Q-08

    Which readiness capabilities have been tested, and which are only planned?

    Readiness capability register; first output: rung evidence for 15 functions.

7.2Portfolio proposed for the Q1 2027 alignment

Five initiatives and one Universe mission candidate are proposed for the 2027 genomics portfolio. They are programme objects: no partner, funder or member is attached to them in this edition.

Table 7.1Objects proposed for the first operational quarter
IDObjectKindQuestionState
INI-XT05-DLV-01Delivery and accessInitiativeQ-01PROPOSED
INI-XT05-ENE-02Footprint of genomicsInitiativeQ-02PROPOSED
INI-XT05-CST-03Cost on a common basisInitiativeQ-03PROPOSED
INI-XT05-SUP-04Sequencer supplyInitiativeQ-04PROPOSED
INI-XT05-DIV-05Dataset balanceInitiativeQ-05PROPOSED
MSN-XT05-2027-01Delivery pathway Universe missionMissionQ-01Candidate

7.3The pathway

The genomics edition reads national readiness chapters, the coupled sector reports on health and data, and the global edition through one governed evidence graph. At baseline the federation is designed; the global energy and lifeline editions are drafted. This page states what exists today and what comes next.

  1. 01

    National readiness chapters

    genomic medicine and data-protection readiness in each national edition

    IN PREPARATION · national baselines

  2. 02

    Sector couplings

    GS-04 health · XT-04 biotechnology · XT-10 cryptography

    GS-04 DRAFTED · sector baselines

  3. 03

    Technology system model

    sequencing, data, therapies, trade, workforce, governance

    v0 SPECIFIED · v1 with federation evidence

  4. 04

    Strategic links

    SR-02 lifeline systems · SR-13 strategic technology

    PLANNED · strategic baselines

  5. 05

    Universe

    annual proving environment

    CANDIDATE MISSION · mandate in 2027

  6. 06

    XT-05 report

    this series

    BASELINE DRAFT · 2027 annual edition

  7. 07

    Evidence and correction

    one graph, many projections

    OPEN · first correction cycle in 2027

7.4Universe 2027: evidence pack for the genomics candidate mission

  1. 01

    Mandate

  2. 02

    Core Build · 1 month

  3. 03

    Action · 1 week

  4. 04

    Evidence seal

  5. 05

    Portfolio correction

  6. 06

    Next mandate

Table 7.2Universe 2027: evidence pack for the genomics candidate mission
ItemRecordStateTiming
F1Annual mandate recordPLANNEDafter the Q2 2027 alignment
F2Core Build recordPLANNEDone month before the exercise
F3Exercise evidencePLANNEDduring the Action week
F4Decision packetsPLANNEDexercise state only
F5Proof receiptsPLANNEDscoped to each recorded check
F6After-action reportPLANNEDwithin one quarter
F7Upgrade docketPLANNEDrouted to the Portfolio
F8Portfolio renewalPLANNED2027 global annual edition
F9Public synthesisPLANNEDpublic-safe extracts only

Mission

ID
MSN-XT05-2027-01 · Delivery pathway Universe mission
Role spine
Leadership sponsor · Institutional anchor · Mission lead: drawn from national pathways
Receiving actors
to be identified with the mandate

7.5Handoffs and routing

Where the baseline’s findings go next. A handoff routes a finding for awareness, review or work; it transfers no authority.

Table 7.3Handoffs and routing
FindingRouted toPurposeClass
HLT-001 · sickle cell therapyINI-XT05-DLV-01delivery and accessPUBLIC
HLT-004 · safety eventINI-XT05-DLV-01delivery and accessPUBLIC
DAT-007 · biobanksINI-XT05-DIV-05dataset balancePUBLIC
INF-008 · vendor claimsINI-XT05-CST-03cost on a common basisPUBLIC
ENE-009 · compute footprintINI-XT05-ENE-02 · key F reviewfootprint of genomicsPUBLIC
TRD-010 · tradeINI-XT05-SUP-04sequencer supplyPUBLIC
GOV-011 · approval and governanceregional consortiarule overlayPUBLIC
SYS-012 · compound pathwayMSN-XT05-2027-01Universe candidateCONSORTIUM
Table 7.4Routing rules by publication class
ClassWhere it goesWho can see it
PUBLICthe published edition and its evidence bundleanyone
CONSORTIUMgoverned rooms of the federationconsortium members under agreement
CONTROLLEDneed-to-know channelsnamed competent actors only

7.6Feeds and signal register

Table 7.5Feeds watched from 2027
FeedProducerLatencyFeeds into
Journals and preprints on editing and safetypeer review and preprintscontinuousHLT-001
FDA approvals and guidanceFDAper releaseGOV-011
Biobank data releasesbiobanksper releaseDAT-007
Company results and announcementscompaniesquarterlyFIN-005
Trade and procurement noticesagencies and ministriesper eventTRD-010
Employment projectionsBLSannualFIN-005
Clinical hold and safety noticescompanies and FDAper eventHLT-004

Escalation routes

  • none · keep monitoring
  • research question
  • project
  • risk object
  • annual publication
  • signal report
Table 7.6Signals at baseline
IDSignalCorroborationSystemsRoute
SIG-XT05-001Phase 3 exa-cel results23CORROBORATEDHLTresearch question Q-01
SIG-XT05-002Clinical hold on in vivo editing trials, October 20259PARTIALHLTresearch question Q-01
SIG-XT05-003Vendor price claims for sequencing1415PARTIALINFinitiative Q-03

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 2Frangoul, H. et al., Exagamglogene Autotemcel for Severe Sickle Cell Disease, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 44 treated, 30 evaluable, 29 free of crises for 12 months or more). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  2. 3Locatelli, F. et al., Exagamglogene Autotemcel for Transfusion-Dependent beta-Thalassemia, New England Journal of Medicine 2024 (abstract read through the Europe PMC record; 52 treated, 35 evaluable, 32 transfusion independent). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  3. 9BioSpace (ed.), Life-threatening liver toxicity triggers FDA freeze on two Intellia gene therapy studies (trade press, 30 October 2025; relays company disclosures; secondary report, weak evidence). BioSpace, Boston. Observation year 2025. Accessed 2026-11-03.back
  4. 14Illumina (ed.), NovaSeq X Series product page (vendor claims: 16 to 21 Tb per run for NovaSeq X Plus, more than 128 genomes per run, run time about 14 to 48 hours; vendor evidence, weak). Illumina, San Diego. Observation year 2026. Accessed 2026-11-03.back
  5. 15Ultima Genomics (ed.), germline genetics product page (vendor claim of a USD 60 genome at list price over 4 wafers on the UG200 series; the browser title reads USD 80; vendor evidence, weak). Ultima Genomics, Newark. Observation year 2026. Accessed 2026-11-03.back

Cite this chapter

Valadbaygi, S. (Ed.). (2026). Chapter 7: The 2027 agenda. In Exponential Technology Report 2026: Genomics and Gene Editing (Baseline Edition 2026, Report No. NR-XTECH-GENOMICS-GLOBAL-2026-BASELINE) [Draft under review]. The Global Centre for Risk and Innovation (GCRI).

Every citation form of the whole report, BibTeX and RIS included, is on the edition home. Cite this report

ReportsContribute

Send evidence or a correction on Genomics and Gene Editing.

Reports is the Consortium’s quarterly publication, written by six desks. This page sits with the Global Centre for Risk and Innovation (GCRI) Systems Evidence desk. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work. Sent to the wrong desk, it is forwarded, not refused.

GCRI Systems Evidence deskExponential Technology

Never send personal data, sensitive infrastructure detail or anything you have no right to share. A contribution is reviewed before use; sending it confers no authorship or editorial rights, and sponsorship never buys a finding.

CC BY 4.0 Free to read. Text and figures: CC BY 4.0. Data: CC0 1.0. Authors keep copyright. Published by GCRI Canada.

The Global Centre for Risk and Innovation

Science · evidence · measurement

Not for profit

Our articles, maps and twins are free to read and free to republish. Readers and partners keep it that way.

Partner with us

Who funds us

GCRI is a not-for-profit institution. To ask who funds a piece of work, use the funding questions form.

Independence

Editors and the expert reviewers named on each article decide what we publish. Funders and partners do not review or approve articles before publication.

Corrections policy

Licence

Articles: CC BY 4.0. Figures, maps, twins and data: CC BY 4.0. Other uses: ask through the permissions form.

Privacy choices